Vista Therapeutics, Inc.           Nanotechnology for Molecular Diagnostics And Multiplex Biomarker Measurement           Call us: 1-505-474-3143 | E-mail:

"Experience the enormous power of small"

Vista Founders

Spencer Farr


Spencer Farr, Ph.D. studied engineering and genetics at UC. Berkeley. He earned a Ph.D. in Molecular and Cell Biology at the University of New Mexico School of Medicine and the Institut Jacques Monod in Paris France, where he was a Fulbright Scholar. Spencer was an NIH post-doctoral fellow in Bruce Ames lab at UC. Berkeley and then joined the faculties of Harvard and MIT in molecular toxicology. He was the founder and CEO of Xenometrix Inc., Phase-1 Molecular Toxicology Inc., and Vista Therapeutics, Inc. Vista Therapeutics applies proprietary nanotechnology to the field of clinical medicine and drug development.

Charles M. Lieber


Charles M. Lieber, PhD is the Mark Hyman Professor of Chemistry at Harvard University and is the inventor of biomarker sensing via functionalized silicon nanowires, the core of Vista's technology. Lieber has published over 380 papers in peer-reviewed journals and the principal inventor on more than 40 patents including silicon nanowire sensing.